Prudential Financial
HRTX icon

Prudential Financial’s Heron Therapeutics HRTX Stock Holding History

Prudential Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.8K Buy
+23,495
New +$27.2K ﹤0.01% 2378
2025
Q4 		– Sell
-34,465
Closed -$43.4K – 2311
2025
Q3 		$43.4K Sell
34,465
-2,000
-5% -$3.17K ﹤0.01% 2349
2025
Q2 		$75.5K Buy
36,465
+25,450
+231% +$52K ﹤0.01% 2309
2025
Q1 		$24.2K Buy
+11,015
New +$21.4K ﹤0.01% 2243
2024
Q4 		– Sell
-42,515
Closed -$84.6K – 2455
2024
Q3 		$84.6K Buy
42,515
+12,000
+39% +$28.7K ﹤0.01% 2595
2024
Q2 		$107K Buy
30,515
+17,580
+136% +$54K ﹤0.01% 2538
2024
Q1 		$35.8K Buy
+12,935
New +$32.5K ﹤0.01% 2619
2015
Q1 		– Sell
-10,300
Closed -$104K – 2238
2014
Q4 		$104K Buy
+10,300
New +$84.1K ﹤0.01% 2152

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Prudential Financial's HRTX Position: Q1 2026 in Review

Prudential Financial opened a new position in Heron Therapeutics (HRTX) in Q1 2026: 23,495 shares worth $18.8K. The stake represents ﹤0.01% of the portfolio and ranks #2378 among its holdings. This is a return to the name: Prudential Financial previously reported a position in HRTX as recently as Q3 2025.

Prudential Financial first reported a position in HRTX in Q4 2014 and has held it in 8 quarters since. The position peaked at $107K in Q2 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Prudential Financial held 23,495 shares of Heron Therapeutics worth $18.8K as of Q1 2026.
  • Heron Therapeutics was a new Prudential Financial position in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #2378 holding.
  • Prudential Financial first reported a position in Heron Therapeutics in Q4 2014 and has held it in 8 quarters since.
  • Prudential Financial's Heron Therapeutics position peaked at $107K in Q2 2024.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.